Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

Journal of Neurology

Volumn 262, Issue 2, 2015, Pages 294-306

  Compta, Yaroslau ^a   Valente, Tony ^a   Saura, Josep ^a   Segura, Bàrbara ^a   Iranzo, Álex ^b   Serradell, Mònica ^b   Junqué, Carme ^a   Tolosa, Eduard ^a   Valldeoriola, Francesc ^a   Muñoz, Esteban ^a   Santamaria, Joan ^b   Cámara, Ana ^a   Fernández, Manel ^a   Fortea, Juan ^c   Buongiorno, Mariateresa ^a   Molinuevo, José Luis ^c   Bargalló, Núria ^c   Martí, María José ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Cerebrospinal fluid; Cortical thickness; Dementia; Neuropsychological function; Parkinson s disease; Premotor; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMERIC ALPHA SYNUCLEIN; TOTAL ALPHA SYNUCLEIN; UNCLASSIFIED DRUG; SNCA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; DEMENTIA; FEMALE; FRONTAL LOBE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PARKINSON DISEASE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARASOMNIA; PARKINSON DISEASE; PREMOTOR PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SPEECH SOUND DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE; VISION; CEREBROSPINAL FLUID; COMPLICATION; MIDDLE AGED; PATHOLOGY;

AGED; ALPHA-SYNUCLEIN; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84925498290     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7560-z     Document Type: Article

References (45)

1. Mollenhauer B (2014) Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson’s disease? Parkinsonism Relat Disord 20(Suppl 1):S76–S79
2. Magdalinou N, Lees AJ, Zetterberg H (2014) Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 85:1065–1075
3. Tolosa E, Gaig C, Santamaría J, Compta Y (2009) Diagnosis and the premotor phase of Parkinson disease. Neurology 72:S12–S20
4. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
5. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844
6. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410
7. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133:713–726
8. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766–1772
9. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230–240
10. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O (2011) Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord 26:1428–1435
11. Kang JH, Irwin DJ, Chen-Plotkin AS, Parkinson’s Progression Markers Initiative et al (2013) Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70:1277–1287
12. van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD (2014) Reduced α-synuclein levels in cerebrospinal fluid in Parkinson’s disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 21:388–394
13. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450:332–335
14. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol 7:215–222
15. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33:430.e1–430.e3
16. Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S (2014) Increased CSF α-synuclein levels in Alzheimer’s disease: correlation with tau levels. Alzheimers Dement. doi:10.1016/j.jalz.2013.10.004
17. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108:4194–4199
18. Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P (2014) Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson’s disease. Mov Disord 29(8):1019–1027
19. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442
20. Williams-Gray CH, Foltynie T, Brayne CEG, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798
21. Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, Wolk DA, Moberg PJ, Xie SX, Clark CM (2011) Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 68:1562–1568
22. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, Lomeña F, Vilas D, Lladó A, Gaig C, Santamaria J (2013) Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 12:443–453
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
24. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707
25. Fahn S, Elton RL, Members of the UPDRS Development Committee Unified Parkinson’s disease rating scale (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A (eds) Recent developments in Parkinson’s disease. McMillan Health Care Information, Florham Park, p 153
26. Folstein MF, Folstein SE, McHugh PR (1975) ‘‘Mini-Mental state.’’ A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
27. Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord 24:2203–2210
28. Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment, 4th edn. Oxford University Press Inc., New York
29. Peña-Casanova J, Gramunt-Fombuena N, Quiñones-Ubeda S, Sánchez-Benavides G, Aguilar M, Badenes D, Molinuevo JL, Robles A, Barquero, Payno M, Antúnez C, Martínez-Parra C, Frank-García A, Fernández M, Alfonso V, Sol JM, Blesa R, NEURONORMA Study Team (2009) Spanish multicenter normative studies (NEURONORMA project): norms for the Rey-Osterrieth complex figure (copy and memory), and free and cued selective reminding test. Arch Clin Neuropsychol 24:371–393
30. Peña-Casanova J, Quiñones-Ubeda S, Gramunt-Fombuena N, Aguilar M, Casas L, Molinuevo JL, Robles A, Rodríguez D, Barquero, Antúnez C, Martínez-Parra C, Frank-García A, Fernández M, Molano A, Alfonso V, Sol JM, Blesa R, NEURONORMA Study Team (2009) Spanish multicenter normative studies (NEURONORMA Project): norms for boston naming test and token test. Arch Clin Neuropsychol 24:343–354
31. Peña-Casanova J, Quiñones-Ubeda S, Gramunt-Fombuena N, Quintana-Aparicio M, Aguilar M, Badenes D, Cerulla N, Molinuevo JL, Ruiz E, Robles A, Barquero, Antúnez C, Martínez-Parra C, Frank-García A, Fernández M, Alfonso V, Sol JM, Blesa R, NEURONORMA Study Team (2009) Spanish Multicenter normative Studies (NEURONORMA Project): Norms for verbal fluency tests. Arch Clin Neuropsychol 24:395–411
32. Peña-Casanova J, Quintana-Aparicio M, Quiñones-Ubeda S, Aguilar M, Molinuevo JL, Serradell M, Robles A, Barquero, Villanueva C, Antúnez C, Martínez-Parra C, Frank-García A, Aguilar MD, Fernández M, Alfonso V, Sol JM, Blesa R, NEURONORMA Study Team (2009) Spanish Multicenter normative Studies (NEURONORMA Project): norms for the visual object and space perception battery-abbreviated, and judgment of line orientation. Arch Clin Neuropsychol 24:355–370
33. Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis. I. segmentation and surface reconstruction. Neuroimage 9:179–194
34. Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 97:11050–11055
35. Perneger TV (1998) What’s wrong with Bonferroni adjustments. Br Med J 316:1236–1238
36. Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM (2014) Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 6:25
37. Wennström M, Suroya Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM (2008) Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8:e53250
38. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102–112
39. Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is moreimportant? Brain 134:1493–1505
40. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 98:12245–12250
41. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM (2013) Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154:103–117
42. Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, Valldeoriola F, Muñoz E, Camara A, Buongiorno M, Martí MJ (2012) Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson’s disease and related dementia. Parkinsonism Relat Disord 18:941–947
43. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J, Parkinson Study Group DATATOP Investigators (2014) Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184:966–975
44. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord 27:349–356
45. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J (2012) Phosphorylated α-synuclein in Parkinson’s disease. Sci Trasnl Med 4:121ra20